State payer mandates to cover care in US oncology trials: Do science and ethics matter?

Journal of the National Cancer Institute

Volumn 102, Issue 6, 2010, Pages 376-390

  Taylor, Patrick L ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ETHICS; INSTITUTIONAL REVIEW; INSURANCE; MEDICAID; MEDICARE; ONCOLOGY; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; RESEARCH; SCIENCE; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; ETHICS COMMITTEES, RESEARCH; ETHICS, RESEARCH; GOVERNMENT REGULATION; HUMANS; INSURANCE COVERAGE; MEDICAL ONCOLOGY; MEDICARE; NEOPLASMS; RESEARCH SUBJECTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77949973529     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq028     Document Type: Article

References (27)

1. Medicare Clinical Trial Policies\Overview. http://www.cms.hhs.gov/ ClinicalTrialPolicies/. Accessed December 23, 2009.
2. Hellen Gelband Prepared for the National Cancer Policy Board. A Report on the Sponsors of Cancer Treatment Clinical Trials and Their Approval and Monitoring Mechanisms.Washington DC: Institute of Medicine National Research Council;1999.http://www.nap.edu/readingroom/books/sponcan/. Accessed December 23, 2009.
3. Goldman DP, et al. Incremental treatment costs in National Cancer Institute-sponsored clinical trials. JAMA. 2003;289(22):2970-2977.
4. Unger JM, et al. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006;24 (1):141-144.
5. Henry J. Kaiser Family Foundation. Medicare Enrollment, by Status, 2001-2007. http://facts.kff.org/chart.aspx?ch=376. Accessed December 23, 2009.
6. U.S. Census Bureau. Annual Population Estimates of the United States. http://www.census.gov/popest/states/NST-ann-est.html. Accessed December 23, 2009.
7. Bennett CL, Adams JR, Knox KS, Kelahan AM, Silver SM, Bailes JS. Clinical trials: are they a good buy? J Clin Oncol. 2001;19(23):4330-4339.
8. McBride G. More states mandate coverage of clinical trial costs, but does it make a difference? J Natl Cancer Inst. 2003;95(17):1268-1269. doi:10.1093/jnci/95.17.1268.
9. Kelahan AM. Dissemination of information on legislative mandates and consensus-based programs addressing payment of the costs of routine care in clinical trials through the World Wide Web. Cancer. 2004;100(6): 1238-1245.
10. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283(20):2701-2711.
11. Bankert E, Amdur R. The IRB is not a data safety monitoring board. IRB. 2000;22(6):9-11.
12. DeMets DL, Fost N, Powers M. An institutional review board dilemma: responsible for safety monitoring but not in control. Clin Trials. 2006;3:142-148. doi:10.1191/1740774506cn137oa. (Pubitemid 43829214)
13. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry infuence. JAMA. 2008;299(15):1833-1835.
14. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003;290(4):495-501.
15. The Food and Drug Administration's Oversight of Clinical Trials. Offce of Inspector General, Department of Health and Human Services, September,2007. http://oig.hhs.gov/oei/f.asp#fda. Accessed October 10, 2009.
16. Angell M. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York, NY: Random House; 2004.
17. The Food and Drug Administration's Oversight of Clinical Investigators' Financial Information. Offce of Inspector General, Department of Health and Human Services, January 2009. http://www.oig.hhs.gov/oei/reports/oei-05-07- 00730.pdf. Accessed December 23, 2009.
18. Angell M. Industry-sponsored clinical research: A broken system. JAMA. 2008;300(9):1069-1071.
19. Beh H. Compensation for research injuries. IRB. 2005;27(3):11-14
20. National Bioethics Advisory Commission. Ethical and Policy Issues in Research Involving Human Participants, Report and Recommendations.Bethesda, MD: Government Printing Offce; 2001
21. President's Commission for the Study of Ethical problems in Medicine and Biomedical Research: Compensating for Research Injuries. Vol 1. Washington, DC: Government Printing Offce; 1982.
22. Resnick DB. Compensation for research-related injuries. J Leg Med. 2006;27(3):263-287.
23. Institute of Medicine. Committee on Assessing the System for Protecting Human Research Participants. Responsible Research: A Systems Approach to Protecting Research Participants.Washington, DC: National Academies Press; 2002. http://www.nap.edu/catalog.php?record-id=10508#toc. Accessed December 23, 2009.
24. Steinbrook R. Compensation for research subjects. N Engl J Med. 2006;354(18):1871-1873. Food and Drug Administration Amendments Act of 2007. Public Law 110-85,:121Stat 823, section 801. http://frwebgate.access.gpo.gov/ cgi-bin/getdoc.cgi?dbname=110-cong-public-laws&;docid=f:publ085.110. Accessed December 23, 2009.
25. Schulman KA, Seils DM, Timble JW, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med. 2002;347(17):1335-1341.
26. Mello MM, Clarridge BR, Studdert DM. Academic medical centers' standards for clinical trial agreements with industry. N Engl J Med. 2005; 352(21):2202-2210.
27. Steinbrook R. Gag clauses in clinical-trial agreements. N Engl J Med. 2005;352(21):2160-2162.